Nuclear Perfusion Tomography for the Assessment of the Pulmonary Circulation

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000328976

Enrollment

Registered

2011-03-28

Start date

2011-04-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Pulmonary arterial hypertension (PAH) is a devastating condition with a poor prognosis. There are currently no widely available imaging modality to assess lung perfusion, which is decreased in PAH. Single photon emission computed tomography (SPECT) is a nuclear medicine technique which can assess three dimensional lung perfusion. We wish to evaluate the utility of SPECT in the assessment and early detection of PAH.

Interventions

Participants will undergo a single photon emission computed tomography lung perfusion scan using technetium labelled macroaggregated albumin. The duration of the scan is approximately 30 minutes. All participant groups (healthy controls, high-risk for pulmonary arterial hypertension, and established pulmonary hypertension) will undergo the same intervention.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Control group - No history of cardiac or respiratory disease - Normal spirometry - Normal transthoracic echocardiogram - Smoking history < 10 years - No risk factor for pulmonary hypertension 2. High Risk for PAH Group - History of scleroderma or carrier of BMPR2 mutation - Normal resting pulmonary artery pressure - No significant lung disease 2. Pulmonary arterial hypertension (PAH) group - WHO Classification Group 1 PAH - Pre-capillary pulmonary arterial hypertension confirmed on Right Heart Catheter: mean pulmonary > 25 mm Hg and wedge pressure <15 mm Hg

Exclusion criteria

Pregnancy

Outcome results